

## DAFTAR PUSTAKA

- ACS. (2016). What is breast cancer?. Diakses 6 April 2016, dari <http://www.cancer.org/cancer/breastcancer/detailedguide/breast-cancer-what-is-breast-cancer>.
- Arteaga, C.L., Sliwkowski, M.X., Osborne, C.K., Perez, E.A., Puglisi, F., & Gianni, L. (2012). Treatment of HER-2-positive breast cancer: current status and future perspectives. *National Reviews Clinical Oncology*. Vol. 9. Pp.16–32.
- Aryandono, T. (2006). *Faktor Prognosis Kanker Payudara Operabel di Yogyakarta. Disertasi Doktor*. Universitas Gadjah Mada, Yogyakarta.
- Australian Institute of Health and Welfare. (2012). *Breast cancer in Australia an overview*. Canberra.
- Biganzoli, L. (2009). Prognostic and Predictive Factors. *Cancer Treatment and Research*. Vol. 151. Pp. 14-26.
- Bjorndahl, M. A., Cao, R., Burton, J. B., Brakenhielm, E., Religa, P., Galter, D., et al. (2005). Vascular endothelial growth factor-A promotes peritumoral lymphangiogenesis and lymphatic metastasis. *Cancer Res*, vol 65(20) : pp. 9261-9268.
- Cianfrocca, M., & Goldstein, L.J. (2004). Prognostic and Predictive Factors in Early-Stage Breast Cancer. *The Oncologist*. Vol. 9. pp. 606-616
- Citri, A., & Yarden, Y. (2006). EGF–ERBB signalling: towards the systems level. *Nature Reviews Molecular Cell Biology*. Vol. 7. Pp. 505-516.
- Clark, G.M. (2000). Prognostic and Predictive Factors, In: Harris J.R., Lippman M.E., Morrow M., & Osborn C.K. *Disease of The Breast (2<sup>nd</sup> ed.)*. Phyladelphia: Lippincot William Wilkins, pp. 489-508.
- Curigliano, G., Viale, G., Bagnardi, V., Fumagalli, L., Locatelli, M., Rotmensz, N., et al. (2009). Clinical Relevance of *HER-2* Overexpression/Amplification in Patients With Small Tumor Size and Node-Negatif Breast Cancer. *Journal Of Clinical Oncology*.vol. 27. Pp. 5693-5699.
- Elledge, R.M., Clark, G.M., Chamness, G.C., & Osborne, C.K. (1994). Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. *Journal of the National Cancer Institute*. Vol. 86, No. 9. Pp. 705-712.

- Ellis, I.O., Schinitt, S.J., & Sastre, G.X. (2003). Invasive Breast Carcinoma in World Health Organization Classification of Tumours Pathology & Genetics Tumours of the Breast and Female Genital Organs. *IARC*. pp 13-59.
- Elston, C.W., & Ellis, I.O. (1991). Pathological Prognostic Factors in Breast Cancer I. The Value of Histological *Grade* in Breast Cancer. Experience from a Large Study and Long-term Follow-Up. *Histopathology*. 19:403.
- Fan, Y. X., Wong, L., Ding, J., Spiridonov, N. A., Johnson, R. C., & Johnson, G. R. (2008). Mutational activation of ErbB2 reveals a new protein kinase autoinhibition mechanism. *J. Biol.Chem.* 283, 1588–1596.
- Fitzgibbons, P.L., Page, D.L., Weaver, D., Thor, A.D., Allred, D.C., & Clark, G.M. (2000). Prognostic Factors in Breast Cancer. *Archives of Pathology & Laboratory Medicine: June 2000*, Vol. 124, No. 7, pp. 966-978.
- Geer, P.V.D., Hunter, T., & Lindberg, R.A. (1994). Receptor Protein-Tyrosine Kinases and Their Signal Transduction Pathways. *Annual Review of Cell Biology*. Vol. 10. Pp. 251-337.
- GLOBOCAN (2012).*Cancer Fact Sheets*.diakses 6 April 2016, dari [http://globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx](http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx) .
- Goldhirsch, A., Glick, J.H., Gelber, R.D., Coates, A.S., Thurlimann, B., Senn, H.J., et al. (2005). Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer. *Annals of Oncology*. Vol.16. pp. 1569–1583.
- Hidayat, A.A. (2009). *Metode Penelitian Kebidanan dan Teknik Analisis Data*. Jakarta: Salemba Medika
- Hoff, E.R., Tubbs, R.R., Myles, J.L., & Procop, G.W. (2002). HER-2/neu Amplification in Breast Cancer Stratification by Tumor Type and *Grade*. *American Journal of Clinical Pathology*. Vol. 117. Pp. 916-921.
- Incorvati, J.A., Shah, S., Mu, Y., & Lu, J. (2013). Targeted therapy for HER-2 positive breast cancer. *Journal of Hematology & Oncology*. Vol. 6(38).
- Kementrian Kesehatan Republik Indonesia. (2015). *Panduan Nasional Penanganan Kanker Payudara*. Jakarta.
- Kumar, V., Abbas, A.K., & Aster, J.C. (2015). *Robbins and Kontran Pathologic Basic of Disease (9<sup>th</sup> ed)*. Philadelphia: Elsevier Saunders.

- Lee, A., Park, W.C., Yim, H.W., Lee, M.A., Park, G., & Lee, K.Y. (2007). Expression of c-erbB2, cyclin D1 and Estrogen Receptor and their Clinical Implications in the Invasive Ductal Carcinoma of the Breast. *Japan Journal of Clinical Oncology*. 37(9): pp 708-714.
- Lee, H.J., Kim, J.Y., Park, S.Y., Park, I.A., Song, I.H., Yu, J.H., et al. (2015). Clinicopathologic Significance of the Intratumoral Heterogeneity of *HER-2* Gene Amplification in *HER-2*- Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab. *Americal Journal Of Clinical Pathology*. Vol. 144(4). Pp.570-578.
- Lee, J. W., Soung, Y. H., Seo, S. H., Kim, S. Y., Park, C. H., Wang, Y. P., et al. (2006). Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. *Clin. CancerRes*. 12, 57–61.
- Moasser, M.M. (2007). The oncogene *HER-2*; Its signaling and transforming functions and its role in human cancer pathogenesis. *Oncogene*. Vol. 26(45). Pp. 6469–6487.
- Naeem, M., Nasir, A., Aman, Z., Ahmad, T., & Samad, A. (2008). Frequency Of Her-2/Neu Receptor Positivity And Its Association With Other Features Of Breast Cancer. *Journal of ayub medical college Abbottabad*. Vol. 20(3). Pp. 23-26.
- Nugraha, S.B. (2007). *Hubungan Antara Hasil Pemeriksaan HER-2/Neu Metode MLPA Dengan Reseptor Hormonal, Klinikopatologis Dan Angka Ketahanan Hidup Penderita Kanker Payudara Di Yogyakarta*. Tesis strata dua, Universitas Gadjah Mada, Yogyakarta.
- Nursalam. (2008). *Konsep dan Penerapan Metodologi Penelitian Ilmu Keperawatan: Pedoman Skripsi, Tesis, dan Instrumen Penelitian Keperawatan, 2nd ed.* Jakarta: Salemba Medika.
- Onitilo, A.A., Engel, J.M., Greenlee, R.T., & Mukesh, B.N. (2009). Breast Cancer Subtypes Based on ER/PR and *HER-2* Expression: Comparison of Clinicopathologic Features and Survival. *Clinical Medicine & Research*. vol. 7. pp. 4-13.
- Park, B.W., Kim, S.I., Kim, E.K., Yang, W.I., & Lee, K.S. (2002). Impact of Patient Age on the Outcome of Primary Breast Carcinoma. *Journal of Surgical Oncology*. Vol. 80. Pp. 12-18.
- Payne S.J.L., Bowen R.L., Jones J.L., & Wells C.A. (2008). Predictive markers in breast cancer. *The present Histopathology*; 52: pp. 82-90

- Pierce, L., Fowble, B., Solin, L.J., Schultz, D.J., Rosser, C., & Goodman, R.L. (1992). Conservative surgery and radiation therapy in black women with early stage breast cancer. Patterns of failure and analysis of outcome. *Cancer*. Vol. 69(11), pp. 2831–2841.
- Pike, M.C., Spicer, D.V., & Dahmouch, L. (1993). Estrogen, Progesteron Normal Breast Cell Proliferation And Breast Cancer Risk. *Epidemiology Reviews*. Vol. 15. Pp. 17-23.
- Price, S.A., & Wilson, L.M. (2006). *Patofisiologi Konsep Klinis Proses-proses Penyakit (6<sup>th</sup> ed)*. Jakarta: EGC.
- Pusat Data dan Informasi Kementerian Kesehatan RI. Stop Kanker, (2015). Diakses 18 Maret 2016, dari <http://www.depkes.go.id/download.php?file=download/pusdatin/infodatin/infodatin-kanker.pdf>.
- Rakha, E.A., Reis-Filho, J.S., Baehner, F., Dabbs, D.J., Deckers, T., Eusebi, V., *et al.* (2010). Breast cancer prognostic classification in the molecular era: the role of histological grade. *Breast Cancer Research*. (<http://breast-cancer-research.com/content/12/4/207>, diakses 24 Maret 2016).
- Rosai, J. (2004). *Breast. In Rosai and Ackerman's Surgical Pathology, 9th ed.* Philadelphia : Elsevier.
- Rosen, P.P., Groshen, S., Saigo, P.E., Kinne, D.W., & Hellman, S. (1989). Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. *Journal of Clinical Oncology*, Vol 7, pp. 1239-1251
- Ross, D.F., & Niederhuber, J.E. (2005). *Breast Cancer (2<sup>nd</sup> ed)*. Philadelphia: Elsevier Churchill Livingstone.
- SEER. (2016). SEER Stat Fact Sheets: Female Breast Cancer. Diakses 6 April 2016, dari <http://seer.cancer.gov/statfacts/html/breast.html>.
- Schitt, S.J., & Guidi, A.J. (2000). Pathology and Biological Markers of Invasive Breast Carcer. In: Harris, J.R., Lippman, M.E., Morrow, M., & Osborn, C.K. *Disease of The Breast (2<sup>nd</sup> ed.)*. Phyladelphia: Lippincot William Wilkins, pp. 425-470.
- Solinas, G., Germano, G., Mantovani, A., & Allavena, P. (2009). Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. *J Leukoc Biol*, vol. 86(5). Pp. 1065-1073.

- Stephens, P., Hunter, C., Bignell, G., Edkins, S., Davies, H., Teague, J., *et al.* (2004). Lung cancer: intra-genic ERBB2 kinase mutations in tumours. *Nature* 431, 525–526.
- Traina, A., Agostara, B., Marasa, L., Calabro, M., Zarccone, M., Carruba, G. (2006). HER2/neu Expression in Relation to Clinicopathologic Features of Breast Cancer Patients. *Annals New York Academy of Sciences* 1089 ; 159-167.
- WHO. (2016). Cancer Fact Sheet. Diakses 6 April 2016, dari [http://www.searo.who.int/entity/noncommunicable\\_diseases/advocacy/cancer\\_fact\\_sheet.pdf?ua=1](http://www.searo.who.int/entity/noncommunicable_diseases/advocacy/cancer_fact_sheet.pdf?ua=1).
- Yager, J.D., & Davidson, N.E. (2006). Mechanisms of disease, Estrogen Carcinogenesis in Breast Cancer. *New England Journal of Medicine*; 354: 270-282.